Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The Mycotic Ulcer Treatment Trial: A Randomized Trial Comparing Natamycin vs Voriconazole

Open access
Prajna, N. Venkatesh, Krishnan, Tiruvengada, Mascarenhas, Jeena, Rajaraman, Revathi, Prajna, Lalitha, Srinivasan, Muthiah, Raghavan, Anita, Oldenburg, Catherine E., Ray, Kathryn J., Zegans, Michael E., McLeod, Stephen D., Porco, Travis C., Acharya, Nisha R., Lietman, Thomas M., Mycotic Ulcer Treatment Trial Group, for the · 2013 · JAMA Ophthalmology

Abstract

OBJECTIVE: To compare topical natamycin vs voriconazole in the treatment of filamentous fungal keratitis. METHODS: This phase 3, double-masked, multicenter trial was designed to randomize 368 patients to voriconazole (1%) or natamycin (5%), applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks. Eligibility included smear-positive filamentous fungal ulcer and visual acuity of 20/40 to 20/400. MAIN OUTCOME MEASURES: The primary outcome was best spectacle-corrected visual acuity at 3 months; secondary outcomes included corneal perforation and/or therapeutic penetrating keratoplasty. RESULTS: A total of 940 patients were screened and 323 were enrolled. Causative organisms included Fusarium (128 patients [40%]), Aspergillus (54 patients [17%]), and other filamentous fungi (141 patients [43%]). Natamycintreated cases had significantly better 3-month best spectacle-corrected visual acuity than voriconazole-treated cases (regression coefficient=0.18 logMAR; 95% CI, 0.30 to 0.05; P=.006). Natamycin-treated cases were less likely to have perforation or require therapeutic penetrating keratoplasty (odds ratio=0.42; 95% CI, 0.22 to 0.80; P=.009). Fusarium cases fared better with natamycin than with voriconazole (regression coefficient=0.41 logMAR; 95% CI,0.61 to 0.20; P<.001; odds ratio for perforation=0.06; 95% CI, 0.01 to 0.28; P<.001), while non-Fusarium cases fared similarly (regression coefficient=0.02 logMAR; 95% CI, 0.17 to 0.13; P=.81; odds ratio for perforation=1.08; 95% CI, 0.48 to 2.43; P=.86). CONCLUSIONS: Natamycin treatment was associated with significantly better clinical and microbiological outcomes than voriconazole treatment for smear-positive filamentous fungal keratitis, with much of the difference attributable to improved results in Fusarium cases. APPLICATION TO CLINICAL PRACTICE: Voriconazole should not be used as monotherapy in filamentous keratitis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00996736

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaophthalmol.2013.1497

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 348

Metadata

Authors
Prajna, N. V., Krishnan, T., Mascarenhas, J., Rajaraman, R., Prajna, L., Srinivasan, M., Raghavan, A., Oldenburg, C. E., Ray, K. J., Zegans, M. E., McLeod, S. D., Porco, T. C., Acharya, N. R., Lietman, T. M., & Mycotic Ulcer Treatment Trial Group, F. T.
Venue
JAMA Ophthalmology
Published
2013-04-01
Volume
131
Issue
4
Pages
422
ISSN
2168-6165 (ISSN-L)
OpenAlex
W2001276323
Cited by
348
References
14
FWCI
11.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Mycotic Ulcer Treatment Trial: A Randomized Trial Comparing Natamycin vs Voriconazole. https://app.cochat.ai/papers/10.1001/jamaophthalmol.2013.1497
The paper
Prajna, N. V., Krishnan, T., Mascarenhas, J., Rajaraman, R., Prajna, L., Srinivasan, M., Raghavan, A., Oldenburg, C. E., Ray, K. J., Zegans, M. E., McLeod, S. D., Porco, T. C., Acharya, N. R., Lietman, T. M., & Mycotic Ulcer Treatment Trial Group, F. T. (2013). The Mycotic Ulcer Treatment Trial: A Randomized Trial Comparing Natamycin vs Voriconazole. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2013.1497

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.